Your current location: 99jili >>is jili777 legit or not >>main body

lodibet bet

https://livingheritagejourneys.eu/cpresources/twentytwentyfive/    lodibet vip login app  2025-01-26
  

lodibet bet

Polls open in the general election on Friday, but have you decided which party will get your vote? If not, you can read the manifesto of each of the main parties on this page, to see where they stand on the most important issues to you. Advertisement A manifesto is the list of pledges parties make to voters, explaining what they would do if elected. Some of the headline promises made by the main parties include: Fine Gael wants to cut taxes by €7 billion and establish a savings account for every newborn in Ireland, which will have a State contribution of €1,000. Fianna Fáil has pledged to reform health services and cut waiting times for patients, accelerate home building and decriminalise the possession of drugs for personal use. Sinn Féin wants to deliver a mini-budget in its first 100 days of government and “real” cost-of-living measures. The Social Democrats pledge the delivery of 50,000 affordable homes in the lifespan of the next government and the full implementation of the Sláintecare healthcare reforms. Labour has proposed that parents would be able to take a full year of parental leave, as well as introducing pay-related maternity benefit. The Green Party has pledged to spend €10 billion on public transport, impose a tax on business class flights and private jets, and create a State-led childcare system. People Before Profit has called for the foundation of a State construction company to build 30,000 social and 5,000 affordable housing units per year, financed through the Apple back taxes. Independent Ireland wants to a make new independent oversight body – recruited from the private sector – to “tackle Government waste, radically improve efficiency and deliver accountability”. Aontú pledges to tackle waste in public spending and create a new agency for “border control, processing of applications and enforcement”. The full version of each manifesto can be viewed below to compare where the parties stand on the key issues. Fine Gael – "Securing your future" Fianna Fáil – "Moving Forward. Together" Sinn Féin – "The choice for change" Green Party – "Towards 2030. A decade of change"  Social Democrats – "For the Future" Labour Party – "Building Better Together" Independent Ireland – "Common Sense Solutions for a Better Ireland" Aontú – "Our Common Sense Manifesto" People Before Profit – "Another Ireland is possible"Pathstone Holdings LLC lowered its holdings in shares of West Pharmaceutical Services, Inc. ( NYSE:WST – Free Report ) by 5.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 22,821 shares of the medical instruments supplier’s stock after selling 1,420 shares during the quarter. Pathstone Holdings LLC’s holdings in West Pharmaceutical Services were worth $6,850,000 at the end of the most recent quarter. Several other institutional investors have also modified their holdings of WST. Northwest Investment Counselors LLC bought a new position in West Pharmaceutical Services in the third quarter valued at approximately $30,000. Crewe Advisors LLC boosted its stake in West Pharmaceutical Services by 322.7% in the 2nd quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 71 shares during the period. Quest Partners LLC increased its holdings in West Pharmaceutical Services by 5,633.3% during the 2nd quarter. Quest Partners LLC now owns 172 shares of the medical instruments supplier’s stock worth $57,000 after purchasing an additional 169 shares in the last quarter. Blue Trust Inc. raised its stake in shares of West Pharmaceutical Services by 332.1% in the 2nd quarter. Blue Trust Inc. now owns 242 shares of the medical instruments supplier’s stock valued at $80,000 after purchasing an additional 186 shares during the period. Finally, Eastern Bank bought a new stake in shares of West Pharmaceutical Services in the third quarter valued at about $82,000. Institutional investors own 93.90% of the company’s stock. Insider Buying and Selling In other West Pharmaceutical Services news, VP Charles Witherspoon sold 703 shares of the company’s stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $310.40, for a total transaction of $218,211.20. Following the sale, the vice president now directly owns 1,253 shares of the company’s stock, valued at approximately $388,931.20. This represents a 35.94 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink . 0.53% of the stock is currently owned by corporate insiders. West Pharmaceutical Services Stock Down 1.3 % West Pharmaceutical Services ( NYSE:WST – Get Free Report ) last announced its quarterly earnings data on Thursday, October 24th. The medical instruments supplier reported $1.85 EPS for the quarter, topping analysts’ consensus estimates of $1.50 by $0.35. The business had revenue of $746.90 million for the quarter, compared to analyst estimates of $709.62 million. West Pharmaceutical Services had a net margin of 17.37% and a return on equity of 18.41%. The firm’s revenue for the quarter was down .1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.16 earnings per share. On average, sell-side analysts expect that West Pharmaceutical Services, Inc. will post 6.67 EPS for the current fiscal year. West Pharmaceutical Services Increases Dividend The business also recently announced a quarterly dividend, which was paid on Wednesday, November 20th. Investors of record on Wednesday, November 13th were given a $0.21 dividend. The ex-dividend date of this dividend was Wednesday, November 13th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.27%. This is an increase from West Pharmaceutical Services’s previous quarterly dividend of $0.20. West Pharmaceutical Services’s payout ratio is currently 12.46%. West Pharmaceutical Services Profile ( Free Report ) West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. See Also Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. ( NYSE:WST – Free Report ). Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter .Judge rejects request to sideline San Jose State volleyball player on grounds she’s transgenderlodibet bet



The stock market is soaring. Wall Street's biggest names say to be careful.‘It’s boorish’: E-scooter firms threaten to leave Italy after highway code updated

By KENYA HUNTER, Associated Press ATLANTA (AP) — As she checked into a recent flight to Mexico for vacation, Teja Smith chuckled at the idea of joining another Women’s March on Washington . As a Black woman, she just couldn’t see herself helping to replicate the largest act of resistance against then-President Donald Trump’s first term in January 2017. Even in an election this year where Trump questioned his opponent’s race , held rallies featuring racist insults and falsely claimed Black migrants in Ohio were eating residents’ pets , he didn’t just win a second term. He became the first Republican in two decades to clinch the popular vote, although by a small margin. “It’s like the people have spoken and this is what America looks like,” said Smith, the Los Angeles-based founder of the advocacy social media agency, Get Social. “And there’s not too much more fighting that you’re going to be able to do without losing your own sanity.” After Trump was declared the winner over Democratic Vice President Kamala Harris , many politically engaged Black women said they were so dismayed by the outcome that they were reassessing — but not completely abandoning — their enthusiasm for electoral politics and movement organizing. Black women often carry much of the work of getting out the vote in their communities. They had vigorously supported the historic candidacy of Harris, who would have been the first woman of Black and South Asian descent to win the presidency. Harris’ loss spurred a wave of Black women across social media resolving to prioritize themselves, before giving so much to a country that over and over has shown its indifference to their concerns. AP VoteCast , a survey of more than 120,000 voters, found that 6 in 10 Black women said the future of democracy in the United States was the single most important factor for their vote this year, a higher share than for other demographic groups. But now, with Trump set to return to office in two months, some Black women are renewing calls to emphasize rest, focus on mental health and become more selective about what fight they lend their organizing power to. “America is going to have to save herself,” said LaTosha Brown, the co-founder of the national voting rights group Black Voters Matter. She compared Black women’s presence in social justice movements as “core strategists and core organizers” to the North Star, known as the most consistent and dependable star in the galaxy because of its seemingly fixed position in the sky. People can rely on Black women to lead change, Brown said, but the next four years will look different. “That’s not a herculean task that’s for us. We don’t want that title. ... I have no goals to be a martyr for a nation that cares nothing about me,” she said. AP VoteCast paints a clear picture of Black women’s concerns. Black female voters were most likely to say that democracy was the single most important factor for their vote, compared to other motivators such as high prices or abortion. More than 7 in 10 Black female voters said they were “very concerned” that electing Trump would lead the nation toward authoritarianism, while only about 2 in 10 said this about Harris. About 9 in 10 Black female voters supported Harris in 2024, according to AP VoteCast, similar to the share that backed Democrat Joe Biden in 2020. Trump received support from more than half of white voters, who made up the vast majority of his coalition in both years. Like voters overall, Black women were most likely to say the economy and jobs were the most important issues facing the country, with about one-third saying that. But they were more likely than many other groups to say that abortion and racism were the top issues, and much less likely than other groups to say immigration was the top issue. Despite those concerns, which were well-voiced by Black women throughout the campaign, increased support from young men of color and white women helped expand Trump’s lead and secured his victory. Politically engaged Black women said they don’t plan to continue positioning themselves in the vertebrae of the “backbone” of America’s democracy. The growing movement prompting Black women to withdraw is a shift from history, where they are often present and at the forefront of political and social change. One of the earliest examples is the women’s suffrage movement that led to ratification in 1920 of the 19th Amendment to the Constitution , which gave women the right to vote. Black women, however, were prevented from voting for decades afterward because of Jim Crow-era literacy tests, poll taxes and laws that blocked the grandchildren of slaves from voting. Most Black women couldn’t vote until the Voting Rights Act of 1965. Black women were among the organizers and counted among the marchers brutalized on the Edmund Pettus Bridge in Alabama, during the historic march in 1965 from Selma to Montgomery that preceded federal legislation. Decades later, Black women were prominent organizers of the Black Lives Matter movement in response to the deaths of Black Americans at the hands of police and vigilantes. In his 2024 campaign, Trump called for leveraging federal money to eliminate diversity, equity and inclusion programs in government programs and discussions of race, gender or sexual orientation in schools. His rhetoric on immigration, including false claims that Black Haitian immigrants in Springfield, Ohio, were eating cats and dogs, drove support for his plan to deport millions of people . Tenita Taylor, a Black resident of Atlanta who supported Trump this year, said she was initially excited about Harris’ candidacy. But after thinking about how high her grocery bills have been, she feels that voting for Trump in hopes of finally getting lower prices was a form of self-prioritization. “People say, ‘Well, that’s selfish, it was gonna be better for the greater good,”’ she said. “I’m a mother of five kids. ... The things that (Democrats) do either affect the rich or the poor.” Some of Trump’s plans affect people in Olivia Gordon’s immediate community, which is why she struggled to get behind the “Black women rest” wave. Gordon, a New York-based lawyer who supported the Party for Socialism and Liberation’s presidential nominee, Claudia de la Cruz, worries about who may be left behind if the 92% of Black women voters who backed Harris simply stopped advocating. “We’re talking millions of Black women here. If millions of Black women take a step back, it absolutely leaves holes, but for other Black women,” she said. “I think we sometimes are in the bubble of if it’s not in your immediate circle, maybe it doesn’t apply to you. And I truly implore people to understand that it does.” Nicole Lewis, an Alabama-based therapist who specializes in treating Black women’s stress, said she’s aware that Black women withdrawing from social impact movements could have a fallout. But she also hopes that it forces a reckoning for the nation to understand the consequences of not standing in solidarity with Black women. “It could impact things negatively because there isn’t that voice from the most empathetic group,” she said. “I also think it’s going to give other groups an opportunity to step up. ... My hope is that they do show up for themselves and everyone else.” Brown said a reckoning might be exactly what the country needs, but it’s a reckoning for everyone else. Black women, she said, did their job when they supported Harris in droves in hopes they could thwart the massive changes expected under Trump. “This ain’t our reckoning,” she said. “I don’t feel no guilt.” AP polling editor Amelia Thomson DeVeaux and Associated Press writer Linley Sanders in Washington contributed to this report. The Associated Press Health and Science Department receives support from the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

Celta fight back to hold 10-man Barca to 2-2 drawAremu Afolayan breaks down in tears, apologises to his elder brother Kunle in moving video

Alien abduction crews always come in teams of four beings claims abducteeWNBA star Kelsey Plum slams restaurant chain for making her sick

BRIDGEWATER, NEW JERSEY / ACCESSWIRE / December 6, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced it has entered into a securities purchase agreement to raise gross proceeds of approximately $2.02 million through a private placement. The agreement includes the issuance of 961,446 shares of common stock (or common stock equivalents) and warrants to purchase up to an additional 480,723 shares of common stock. Each share (or common stock equivalent) is priced at $2.10 and is accompanied by a warrant. The warrants will have an exercise price of $2.031 per share, becoming exercisable six months after issuance and expiring five and one-half years from the date of issuance. The closing of this transaction is expected on or about December 9, 2024, subject to customary closing conditions. Strategic Investors and Placement Details The financing was led by Gravitas Capital and SDS Capital Group, alongside other biotechnology-focused private investors. President Street Global served as the exclusive placement agent for the offering, ensuring seamless execution of the transaction. After deducting placement agent fees and other offering-related expenses, the Company intends to allocate the net proceeds toward clinical development, including advancing its flagship TH104 development program, as well as general working capital. Advancing Innovation in Biotechnology This financing reinforces Tharimmune's commitment to advancing its portfolio of therapeutic candidates. TH104, the Company's lead clinical asset, is designed to address chronic pruritus associated with primary biliary cholangitis (PBC), a rare and challenging autoimmune liver disease. Regulatory Details The securities in this private placement were offered under Section 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D thereunder. The shares of common stock and underlying warrants are not registered under the Securities Act or state securities laws. The Company has agreed to file a resale registration statement covering these securities to enable their future trading upon registration or qualification under applicable laws. About Tharimmune Tharimmune, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies in immunology, inflammation, and oncology. The Company's lead product candidate, TH104, leverages a unique transdermal buccal film technology designed to address inflammatory conditions, including pruritus associated with PBC. Tharimmune is also advancing TH023, an oral TNF-alpha inhibitor, and exploring novel multi-specific biologics targeting solid tumors. Through a licensing agreement with OmniAb, Inc., the Company harnesses cutting-edge antibody discovery platforms to target specified disease markers. Learn more at www.tharimmune.com . Forward-Looking Statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding the timing and design of Tharimmune's future Phase 2 trial, Tharimmune's strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "depends," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "target," "should," "will," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Factors that may cause such differences, include, but are not limited to, those discussed under Risk Factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2023 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date of this release. Subsequent events and developments may cause the Company's views to change; however, the Company does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this release. Contact Information Tharimmune, Inc. ir@tharimmune.com Alliance Advisors IR Tirth T. Patel tpatel@allianceadvisors.com 212-201-6614 SOURCE: Tharimmune, Inc. View the original on accesswire.com

Tag:lodibet bet
Source:  lodibet free download   Edited: jackjack [print]